Scientific and Clinical Advisors

Dr. Corte is a Consultant Respiratory Physician and Director of Interstitial Lung Disease in the Department of Respiratory Medicine at Royal Prince Alfred Hospital, and Clinical Professor at the University of Sydney. She is Chief Investigator on the Centre of Research Excellence for Pulmonary Fibrosis, which strives to improve and extend the lives of patients living with pulmonary fibrosis through the development of a comprehensive and integrated program of basic and clinical research and education across Australia.  She is the founding Chair of the Steering Committee for the Australian Idiopathic Pulmonary Fibrosis Registry, the Australasian Interstitial Lung Disease Registry, and leads her clinical and translational Pulmonary Fibrosis research group at the University of Sydney.

Professor Corte trained in respiratory medicine at the University of New South Wales in Sydney, Australia. She served as Clinical Fellow in Interstitial Lung Disease at the Royal Brompton Hospital in London with Professor Athol Wells, and earned a doctor of philosophy degree in the identification of pulmonary vascular dysfunction in interstitial lung disease.

Dr. Glaspole is the head of the Alfred Hospital interstitial lung disease clinic and an adjunct clinical associate professor within the Monash University Faculty of Medicine. He is the chair of the Pulmonary Fibrosis Australasian Clinical Trials Network, and an associate investigator in the Centre for Research Excellence in Pulmonary Fibrosis.

Dr. Maher has spent the last 20 years specializing in the management of all forms of pulmonary fibrosis and orphan interstitial lung diseases. He previously ran the ILD unit at Royal Brompton Hospital, London. Since June 2020 he has been Director of ILD at Keck Medicine of University of Southern California in Los Angeles. He remains Professor of Interstitial Lung Disease at Imperial College London. His research interests include; biomarker discovery (including spirometry and physiological biomarkers), the lung microbiome and host immune response in the pathogenesis of IPF and clinical trials in interstitial lung disease. He has been involved in >80 trials in fibrotic lung disease from phase 1b through to phase 4 and including those assessing IPF, sarcoidosis, scleroderma, rheumatoid arthritis and inflammatory myositis. He is an associate editor for American Journal of Respiratory and Critical Care Medicine and European Respiratory Review and is on the Editorial Board of Lancet Respiratory Medicine. He has authored over 380 papers and book chapters on pulmonary fibrosis.

Dr. Molyneaux is a professor of Interstitial Lung disease at Imperial College London. He is the Asthma and Lung UK Chair of Respiratory Research. He is a consultant in Interstitial lung disease and the director of the NIHR Cardiorespiratory Clinical research facility at the Royal Brompton Hospital. He runs an active clinical and translational research program that oversees a team of basic scientists and clinical trial research staff.